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ABSTRACT. Osteogenesis imperfecta (OI) is a Mendelian disease with 
genetic heterogeneity characterized by bone fragility, recurrent fractures, 
blue sclerae, and short stature, caused mostly by mutations in COL1A1 
or COL1A2 genes, which encode the pro-α1(I) and pro-α2(I) chains of 
type I collagen, respectively. A Brazilian family that showed variable 
expression of autosomal dominant OI was identified and characterized. 
Scanning for mutations was carried out using SSCP and DNA sequence 
analysis. The missense mutation c.3235G>A was identified within exon 
45 of the COL1A1 gene in a 16-year-old girl diagnosed as having OI 
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type I; it resulted in substitution of a glycine residue (G) by a serine (S) 
at codon 1079 (p.G1079S). The proband’s mother had the disease signs, 
but without bone fractures, as did five of nine uncles and aunts of the 
patient. All of them carried the mutation, which was excluded in four 
healthy brothers of the patient’s mother. This is the first description in a 
Brazilian family with OI showing variable expression; only one among 
seven carriers for the c.3235G>A mutation developed bone fractures, 
the most striking clinical feature of this disease. This finding has a 
significant implication for prenatal diagnosis in OI disease.
Key words: COL1A1 gene mutations; c.3235G>A; Genetic counseling; 
Intrafamilial variability; Osteogenesis imperfecta 
INTRODUCTION
Osteogenesis imperfecta (OI) is a Mendelian disorder of connective tissue character-
ized by fragile bones and increased susceptibility to fracture. The traditional classification of 
Sillence et al. (1979), based on clinical and radiographic findings that include types I (MIM# 
166200), II (MIM# 166210), III (MIM# 259420), and IV (MIM# 166220), has been expanded 
(Glorieux et al., 2000, 2002; Ward et al., 2002; Morello et al., 2006; Cabral et al., 2007; Van 
Dijk et al., 2009; Alanay et al., 2010; Forlino et al., 2011). The clinical phenotype ranges in 
severity from perinatal lethal, with multiple intrauterine fractures, to mild disease, with rela-
tively few fractures and normal mobility (Chang et al., 2010).
Because collagen is the major matrix protein of all connective tissues (skin, ligament, 
cartilage, bone, and tendon), defects in type I procollagen synthesis or structure are responsible for 
the majority of clinical OI outcomes. Most OI cases are due to mutations in type I collagen genes, 
COL1A1 and COL1A2, encoding the pro-α1(I) and pro-α2(I) chains, respectively. Nevertheless, 
it has been reported that mutations in prolyl 3-hydroxylation complex [CRTAP (MIM# 605497), 
LEPRE1 (MIM# 610339), and PPIB (MIM# 123841)] and non-collagen related genes [FKBP10 
(MIM# 607063), PLOD2 (MIM# 601865), SERPINF1 (MIM# 172860), SERPINH1 (MIM# 
600943), and SP7 (MIM# 606633)] lead to defective bone development and collagen helix forma-
tion associated with a clinical spectrum of recessive OI (Forlino et al., 2011). Although a decreased 
amount of structurally normal type I collagen in particular is the cause of mild disease (OI type I), 
in patients heterozygous for a nonfunctional COL1A1 allele, a structurally abnormal type I collagen 
protein can be seen in mild to lethal/severe and moderate phenotypes (Galicka et al., 2003). 
The type I collagen triple helix consists of a supercoiled assembly of 3 extended polypro-
line II-like chains. The folding of the 3 chains restricts every third residue to being a Gly, generating 
a repeating (Gly-X-Y)n sequence pattern (Fraser et al., 1979). The most frequent tripeptide unit 
(triplet) is Gly-Pro-Hyp, which constitutes 10% of all triplets and also contributes the maximum 
possible stability to the triple helix (Bhate et al., 2002). Missense mutations in either the pro-α1(I) 
or pro-α2(I) chain, which lead to the substitution of Gly in the ubiquitous Gly-X-Y with bulky 
amino acids such as Arg, Asp, Glu, Cys, Ser, Ala, or Val, result in reduced collagen secretion, 
disruptive folding of the triple helix, decreased thermal stability, and increased post-translational 
modification, depending on the substitution (Bateman et al., 1992; Gauba and Hartgerink, 2008). 
OI type I is the mildest and least deforming disease condition within significant inter-
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familial and intrafamilial heterogeneity, suggesting that factors other than pattern and site of 
collagen gene mutation can influence the clinical phenotype (Primorac et al., 2001). Whereas the 
diagnosis of OI is commonly based on fracture rate, family history, and typical clinical signs, the 
rarity of the condition and its large spectrum of phenotypes can lead to misdiagnosis in asymp-
tomatic members of families with mild OI (Deodhar and Woolf, 2000; Primorac et al. 2001).
In this study, we identified the c.3235G>A (p.G1079S) mutation in the COL1A1 gene 
in an OI familial case showing phenotypic variability: a 16-year-old girl diagnosed with OI 
type I with repeated fractures of both femora, and 6 related carriers who presented mild fea-
tures of OI but had no bone fractures. This report highlights the importance of a molecular 
diagnosis in OI to allow for appropriate genetic counseling and disease prevention.
MATERIAL AND METHODS
All protocols were approved by Hospital Infantil Nossa Senhora da Glória (HINSG) 
Committee on Ethics of Research Involving Human Subjects (protocol 37/05; approval date 
October 3, 2006). Blood samples and clinical data were obtained with written informed con-
sent from all participants. The study comprised an OI type I patient who was seen at HINSG, 
located in Vitória, State of Espírito Santo, Brazilian Southeastern, and 10 of her relatives. The 
diagnosis and classification of OI type I were established by a clinical geneticist according to 
the clinical presentation, which included family history, fracture rate, and clinical and radio-
graphic findings (Sillence et al., 1979). 
Genomic DNA was extracted from peripheral blood samples and stored at 4°C until pro-
cessing. The exons and flanking regions from the COL1A1 gene of the affected patient (Figure 
1) were amplified using a polymerase chain reaction (PCR) technique with previously published 
primers (Körkkö et al., 1998). The PCR was carried out in a 20-μL reaction volume containing 
40 ng genomic DNA, 0.20 mM IllustraTM dNTP set (GE Healthcare, UK), 1X PCR buffer (Invi-
trogenTM, Brazil), 0.50 mM of each the forward and reverse primers (InvitrogenTM), and 1 U Taq 
DNA Polymerase (InvitrogenTM). The PCR conditions were an initial denaturation at 94°C for 
10 min, followed by 95°C for 30 s, 55-76°C for 30 s (each fragment was amplified at a specific 
temperature), and 72°C for 30 s, up to 35 cycles, in a GeneAmp® 9700 or Veriti® thermal cycler 
(Applied Biosystems, USA). 
The c.3235G>A mutation was localized within the exon 45 of the patient’s COL1A1 
gene. To investigate the presence of the mutation in 10 relatives of the patient, PCR 
amplification was performed for the fragment of exon 45 and flanking sequences under 
optimal conditions using 5% dimethyl sulfoxide (Amresco Inc., USA) and 2.50 mM MgCl2 
(InvitrogenTM). The PCR products were checked on a 7% acrylamide gel to verify the quality 
of the products. The search for mutations was performed with single-strand conformation 
polymorphism (SSCP) analysis using 5-7% acrylamide gels and commercial version MDE® 
Mutation Detection Enhancement Gel (Lonza Group Ltd., USA). The mobility pattern of 
DNA fragments on SSCP gels was analyzed after silver staining. Altered PCR products were 
processed and sequenced according to the manual provided by the manufacturer of the ABI 
PRISM® 3100 Genetic Analyzer (Applied Biosystems). To analyze the raw chromatogram 
sequencing data and the accuracy of the nucleotide composition of codons and exon/intron 
junctions, we aligned the sequence traces using GenBank sequences of the COL1A1 gene 
(AF017178 for genomic and NM_000088.3 for complementary DNA) and compared them 
©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research 11 (3): 3246-3255 (2012)
Variable expressivity of osteogenesis imperfecta in a family 3249
to the Database of Collagen Mutations (Dalgleish, 1998; http://www.le.ac.uk/genetics/
collagen [accessed January 24, 2012]).
RESULTS
A 16-year-old Brazilian girl diagnosed with OI type I and having a history of 5 femoral 
fractures (2 on the right and 3 on the left) was studied to identify the genetic cause of her disease. 
The first and last fractures were reported at ages 7 and 16, respectively. At the time of the study, the 
patient weighed 51 kg and had a height of 154 cm. The radiograph of the spinal column showed 
compensatory scoliosis owing to a 1.2-cm shortening in the length of the right leg, although the 
patient walked normally and had no deformities of the long bones (absence of intramedullary rods). 
The hearing of the patient was normal, but blue sclerae and dental manifestations of OI were pres-
ent. Bisphosphonate treatment had been initiated at the time of the first fracture and stopped when 
the patient was 16 years old. The most significant outcome related by the patient after the start of 
treatment was a decrease in bone pain and frequency of fracture. Bone mineral density (BMD) in 
the lumbar spine (LSBMD) and whole body (WBBMD) was evaluated. An increasing in LSBMD 
(from 0.446 g/cm2 to 1.188 g/cm2) and WBBMD (from 0.67 to 1.061 g/cm2) was observed. 
SSCP screening for mutations in the COL1A1 gene of the patient (Figure 1) detected an 
aberrant migration pattern for exon 45 (Figure 2). The DNA sequencing for this abnormal frag-
ment revealed a heterozygous p.G1079S mutation (Figure 3), which was also detected in 6 of the 
patient’s relatives who presented short stature (average = 156.82 ± 16.55 cm), dental manifesta-
tions including teeth fragility, blue sclerae, and hearing loss (auditory device users) but no fractures 
(Table 1). The mutation and clinical aspects described were absent in 3 maternal uncles and the 
maternal grandmother of the patient. The maternal grandfather of the patient was deceased (not an-
alyzed), but family members reported that he had short stature, blue sclera, and teeth abnormalities, 
which suggested that he showed signs of OI. Owing to ethical issues, 12 maternal cousins of the 
patient - 7 of their children from carrier individuals - were not analyzed (not represented in Figure 
1). Their relatives reported that the cousins showed no signs of OI. Although the high miscegena-
tion of Brazilian population, this family showed Caucasian features. The p.G1079S mutation was 
not observed in 100 unrelated normal controls selected from the community of the studied family.
Figure 1. Heredogram of the family with the affected osteogenesis imperfecta patient (black), normal parents 
(white) and parents with blue sclerae, lower stature, fragile teeth, hearing loss, and no fractures (black circle in 
middle). Asterisks indicate that DNA sample is not available for our studies.
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Figure 2. Screening for mutation by single-strand conformation polymorphism. The fragment comprising exon 
45 of the COL1A1 gene from the affected proband (IV-1) and some relatives revealed a subtle difference in the 
mobility when compared to controls (N1-N2).
Figure 3. Schematic view of the α1(I) c.3235G>A (p.G1079S) missense mutation. The arrow signalizes the 
mutation point at the electropherogram from the affected proband (IV-1). Normal sense cDNA strand surrounding 
the mutation site indicating a guanine for adenine in the triplet first nucleotide position (underlined).
Family members Gly901Ser Age (years) Height (cm) Blue sclerae Dental manifestations Hearing loss Bone fractures
IV-1a + 16 155 + + - 5
II-2 - 76 170 - - - -
III-2 - 51 174 - - - -
III-3 - 49 173   - - - -
III-4 + 48 124 + + + -
III-5 + 47 145 + light + + -
III-6 + 45 160 + light + + -
III-8 + 43 144 + light + + -
III-9 + 40 144 + light + + -
III-12 + 37 158 + light + + -
III-13 - 36 178 - - - -
aAffected proband; (+) = presence; (-) = absence.
Table 1. Clinical and genetic descriptions of family members.
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DISCUSSION
In this study, we identified the c.3235G>A (p.G1079S) mutation in the COL1A1 gene 
of a 16-year-old Brazilian girl diagnosed with OI type I who presented repeated bone fractures 
and in 6 of her relatives showing abnormalities in stature, teeth, sclerae, and hearing but no bone 
fractures. These individuals characterize a differential intrafamilial phenotypic expression of OI.
Although many descriptions of the association of OI patients with an absence of bone 
fractures have been presented in the literature, this report is the first of a large Brazilian OI 
familial study (11 relatives) in which 6 individuals who carry a known COL1A1 gene muta-
tion have no bone fractures. Six of the 10 studied siblings had the c.3235G>A mutation, a rare 
genetic change recognized as a pathogenic variant in the etiology of OI, whereas the remain-
ing 4 siblings were not carriers of the mutation. Moreover, one of them had a daughter carrier 
for the mutation who developed repeated bone fractures, which demonstrates the intrafamilial 
phenotypic variability of the disease.
The genetic change observed in 7 distinct individuals and absent in the remaining 
4 of the 11 studied individuals - detected using SSCP analysis (a technique of screening for 
mutations) followed by sequencing of independent amplicons generated with PCR - suggests 
that this finding does not originate from a PCR/SSCP artifact band, which can confuse the 
interpretation of the results. The p.G1079S mutation is outlined as the cause of OI in patients. 
In the present study, this relationship is also supported by the absence of this genetic change in 
100 unrelated normal controls selected from the community of the studied family and by the 
identification of carriers for this mutation who show signs or symptoms of the disease.
The first description of the p.G1079S mutation was reported in an OI type I Italian boy 
and his mother. The 8-year-old patient had repeated fractures of both femora, and his mother, 44 
years old at the time of his birth, had never experienced bone fractures but showed short stature, 
mild hypoacusis, and moderate osteoporosis (Mottes et al., 1992). Other p.G1079S carriers 
have been reported in a Japanese family with juvenile-onset hyperuricemia cosegregated with 
OI. In this family, 2 affected brothers had more than 10 fractures before the age of 13 years, and 
one of them also developed hearing loss and hip joint deformities owing to repeated femoral 
fractures. Their father and brother, also carriers for the same mutation, had no fractures but 
showed blue sclerae, dentinogenesis imperfecta, and joint laxity (Kaneko et al., 2011). Other 
p.G1079S carriers have developed OI type I in familial cases; however, little information about 
the other family members is available in these cases (Hartikka et al., 2004; Roschger et al., 
2008; Zhang et al., 2012). The majority of reported cases of the p.G1079S mutation describe 
mild forms of the disease (OI type I); however, a few reports of patients with OI type IV, a mod-
erate form of the disease, have been published (Dalgleish, 1998; Marini et al., 2007). 
Although only a small number of mild OI familial descriptions appear in the literature, an 
analysis of those cases and of that reported in the current study generally suggests that mutations 
may become more severe in subsequent generations: the parent of a carrier may show abnormali-
ties in sclerae, teeth, and stature without experiencing bone fractures, whereas the next generation 
of carriers may develop bone fractures, mainly in the femora. However, we cannot discard that 
this deduction could be an ascertainment bias because individuals with recurrent fractures require 
medical care, and those in whom this symptom is absent may not be identified because they do 
not request medical assistance and, thus, remain undiagnosed as OI patients. The difference in 
the severity of the disease can also reflect the effect of treatments, for example, bisphosphonate 
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therapy can reduce the frequency of bone fractures and improve the symptoms of OI. 
The occurrence of somatic mosaicism has been proposed to explain the interfamilial 
and intrafamilial variability in the number of fractures and degree of disability in OI (Cohen-
Solal et al., 1996). However, the inheritance pattern observed in our familial study suggests an 
autosomal dominant form instead of somatic mosaicism, because we observed at least 2 gen-
erations and perhaps a third, with individuals showing signs and symptoms of OI (the patient, 
her mother, and possibly her maternal grandfather). 
Some molecular evidence suggests that the p.G1079S mutation causes OI, although 
some carriers do not display bone fractures. This genetic variation results in a glycine (GGC) to 
serine (AGC) missense change in codon 901 of the COL1A1 gene. The most common qualita-
tive mutations in OI are single-nucleotide changes that result in the substitution of Gly residues 
within the Gly-X-Y repeats of the triple helix of the α1(I) and α2(I) chains (Dalgleish, 1998). 
Nearly 100 Gly residue substitutions in the triple-helical domain of the COL1A1 gene are due 
to Ser substitutions. Substitutions of a single Gly by the same residue in different individuals 
frequently have different clinical outcomes. A wide spectrum of phenotypes with Ser for Gly 
substitutions can occur, with outcomes ranging from lethal to nonlethal (Dalgleish, 1998). 
The c.3235G>A mutation (p.G1079S) is located in a cluster that was previously linked 
with nonlethal phenotypes and is surrounded by 2 lethal clusters (Namikawa et al., 1995; Wi-
tecka et al., 2008). Missense mutations in either the pro-α1(I) or pro-α2(I) chains lead to local 
interference with the folding of the triple helix through the substitution of Gly in the ubiqui-
tous Gly-X-Y repeat with bulky amino acids (side chains are larger than that of Gly) such as 
Arg, Asp, Glu, Cys, Ser, Ala, or Val. The disruption in folding in turn causes decreased ther-
mal and helical stability, helix propagation delay, increased levels of lysine post-translational 
modification, and reduced secretion owing to collagen degradation, which causes poor bone 
mineralization and, consequently, the phenotypic expression of the disease (Bateman et al., 
1992; Cabral et al., 2003). The degree of disruption based on the amino acid replacement of 
Gly can be represented as Ala ≤ Ser < Cys < Arg < Val < Glu ≤ Asp (Beck et al., 2000; Buevich 
et al., 2004). The relative clinical severity for various residues replacing Gly shows that the 
more destabilizing Asp, Val, and Arg residues lead to more severe phenotypes than the less 
disruptive Ser, Cys, and Ala residues (Beck et al., 2000). 
A 50% loss of triple helix content and a decrease in thermal stability with effects on 
the folding rate of residues involved in nucleation near the p.G1079S (Ser-901) substitution 
site have been reported (Baum and Brodsky, 1997). Ser-901 might result in a slower folding of 
the protein and extend the time that hydroxylases have to modify lysyl residues in both chains 
of the triple helix (Witecka et al., 2008). Once the triple helix conformation is propagated - in 
a zipper-like mechanism from the C- to N-terminus at a rate limited by cis-trans isomerization 
of amino acid bonds - local sequences N-terminal to the mutation site can also influence the 
propensity for renucleation if the Gly substitution has interrupted the C- to N-terminal propa-
gation of the triple helix. The C- to N-terminal propagation stops at the mutation site with the 
triple helix structured only C-terminal to the mutation site, and independent nucleation events 
N-terminal to the mutation site may be facilitated at Hyp-rich sequences farther downstream 
in the collagen sequence for full-length collagen formation (Buevich et al., 2004). 
It has been proposed that Gly substitutions toward the C-terminus of the α1(I) chains 
result in more clinically severe disease than those toward the N-terminus. Because helix for-
mation propagates from the C- to the N-terminus, mutations toward the C-terminus are more 
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disruptive to helix formation. The best evidence to support this hypothesis comes from the 
αl(I) Gly to Cys mutations that disrupt the close packing of the 3 chains and triggers events 
that lead to defective mineralization of bones (Bateman et al., 1992). Additional evidence 
shows that the effects of type I collagen on thermal unfolding are position-specific such that 
local sequences flanking the Gly substitution and their consequences for collagen structure 
reflect the model of regional effects along the collagen molecule (Westerhausen et al., 1990). 
OI type I is the mildest and least deforming condition of the disease within significant 
interfamilial and intrafamilial heterogeneity. The diagnosis of OI is commonly based on frac-
ture rate, family history, and typical clinical signs, but the rarity of the condition combined 
with the subtle signs of mild OI owing to large phenotypic variability can lead to missed and 
misdiagnosed cases in asymptomatic members of a family with mild OI (Deodhar and Woolf, 
2000; Primorac et al., 2001). The present study finds more evidence that p.G1079S mutation 
is associated with mild OI characterized by short stature, blue sclerae, hypoacusis, dentino-
genesis imperfecta, and bone fragility, among other features. However, bone fracture is not 
a remarkable symptom likely owing to some maintenance of bone integrity. Thus, a bone 
densitometry evaluation is needed to determine whether a real impairment of bone structure 
is present. The intrafamilial variable expressivity due to p.G1079S in the C-terminal region of 
the collagen triple helix might be explained by a possibly less destructive effect of the muta-
tion on collagen fibril performance in some individuals.
In conclusion, strong evidence supports p.G1079S as the cause of OI symptoms. The 
observed phenotypic variability can be explained by environmental factors, such as pharma-
cological treatment (bisphosphonates) that improve the symptoms of the disease, by differ-
ences in the genetic background of patients that can influence bone metabolism and tissue, or 
perhaps by the presence of an unknown locus that can module the phenotype. The phenotypic 
expression in OI depends not only on the nature and position of the mutation but also on a 
combination of multifactorial patterns that determine variability. This study shows that the 
clinical and genetics aspects of OI must be analyzed with caution. The variability in clinical 
expression can make the determination of an accurate prognosis difficult in affected patients, 
but it must be considered for genetic counseling to prevent new OI cases.
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